A randomised, single-blind, crossover comparison of the acceptability of the calcium and vitamin D3 supplements Calcichew D3 Forte and Ad Cal D3 in elderly patients.

Plain-language guide to PMID 11268708 (2001): single-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.

Key Facts

PMID: 11268708
Journal: Current medical research and opinion
Year: 2001
Study type: Randomized Controlled Trial
Authors: Rees TP et al. (2 authors)
DOI: 10.1185/030079901750120178

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

To compare the acceptability of Calcichew D3 Forte (CDF) and Ad Cal D3 (ACD).

Why It Was Studied

The acceptability of the preparation is an important component of the compliance of such patients with their treatment.

Who Took Part

PubMed indexes the participants as middle-aged adults, older adults and people over 80, both men and women.

Patients took CDF for seven days followed by ACD for seven days, or vice versa, according to the randomisation schedule.

At the end of each treatment period, patients used visual analogue scales (VAS) to indicate the grittiness, chalkiness, taste, ease of chewing, ease of swallowing and stickiness of each preparation.

How the Study Was Run

The design is described as randomized, single-blind and crossover.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

In this single-blind Vitamin D, K2, Magnesium and Zinc study one party knew the assignments and the other did not.

Each person switched between Vitamin D, K2, Magnesium and Zinc and the comparison at some point, usually with a gap in between.

This was a randomised, crossover, comparative study of two formulations of calcium and vitamin D.

What Was Measured

PubMed files the paper under topics including Calcium, Drug Combinations, Fractures, Bone, Mastication, Osteoporosis, Patient Acceptance of Health Care and Tablets.

What This Means in Plain Language

The paper is a randomized, single-blind and crossover study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2001 (Current medical research and opinion), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Vitamin D, K2, Magnesium and Zinc in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.